Roflumilast or desloratadine added to usual treatment for rheumatoid arthritis
Tests roflumilast or desloratadine added to standard medicines in adults with rheumatoid arthritis.
Plain-language title generated from the registry record
Registry title: Effect of Roflumilast and Desloratadine as Add-On Therapy in Patients With Rheumatoid Arthritis
Key facts
- Where
- Damietta, EgyptSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT07566351, who can take part
Where in Egypt
- Faculty of Pharmacy, Horus University in EgyptDamietta, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Horus University
- Trial code
- NCT07566351
- Record updated
- 12 May 2026
- Original description
Rheumatoid arthritis is a chronic inflammatory disease that causes joint pain, swelling, and disability. Although standard disease-modifying antirheumatic drugs (DMARDs) are effective for many patients, some individuals continue to experience active disease and inflammation. The aim of this study is to evaluate the effectiveness and safety of adding either roflumilast or desloratadine to standard DMARD therapy in patients with rheumatoid arthritis. Participants will be randomly assigned to receive either roflumilast, desloratadine, or placebo in addition to their usual treatment. The study will assess changes in disease activity, inflammatory biomarkers, and patient-reported outcomes over a three-month follow-up period. The results of this study may help identify new add-on treatment options to improve disease control in patients with rheumatoid arthritis.Read full original descriptionShow less
Clinical Study to Compare the Possible Efficacy and Safety of Roflumilast and Desloratadine as Adjuvant Therapy for Rheumatoid Arthritis
Rheumatoid arthritis is a chronic inflammatory disease that causes joint pain, swelling, and disability. Although standard disease-modifying antirheumatic drugs (DMARDs) are effective for many patients, some individuals continue to experience active disease and inflammation. The aim of this study is to evaluate the effectiveness and safety of adding either roflumilast or desloratadine to standard DMARD therapy in patients with rheumatoid arthritis. Participants will be randomly assigned to receive either roflumilast, desloratadine, or placebo in addition to their usual treatment. The study will assess changes in disease activity, inflammatory biomarkers, and patient-reported outcomes over a three-month follow-up period. The results of this study may help identify new add-on treatment options to improve disease control in patients with rheumatoid arthritis.
Inclusion: Patients with active rheumatoid arthritis according to the 2010 American College of Rheumatology and European League Against Rheumatism classification criteria; Disease activity score in 28 joints (DAS28) greater than 2.6; Age between 18 and 60 years; Male and female patients; Patients receiving methotrexate in addition to standard conventional therapy.
Exclusion: Current treatment with biological disease modifying antirheumatic drugs; Patients with renal or hepatic disease; Known hypersensitivity to the study medications; History of psychiatric disorders; History of cardiac arrhythmias or prolonged QT interval; Use of medications known to prolong the QT interval; Current use of antioxidant supplements; Use of oral prednisolone at a dose greater than 15 mg per day; Pregnant or breastfeeding patients.